Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

FP01

Other · developed by Avalo Therapeutics

Phase 2 Most advanced trial (none active)
AVTX Developer
1 Registered trials

What is FP01?

FP01 is a drug studied in chronic refractory cough. The provided source texts contain no further detail about its molecular nature or mechanism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Respiratory
Developer
Avalo Therapeutics, Inc. (AVTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01703923 Phase 2 Chronic Refractory Cough Completed AVTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Refractory Cough

More from Avalo Therapeutics

AVTX-002 Phase 2 AVTX-009 Phase 2 Camoteskimab Phase 1 CERC-006 Phase 1 CERC-301 Phase 2

Follow AVTX, the company behind FP01

See AVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.